SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-001944 to ALUMIS INC. (ALMS)

ALUMIS INC.
Date: Feb. 19, 2025 · CIK: 0001847367 · Accession: 0000000000-25-001944

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
February 19, 2025
Author
Martin Babler
Form
UPLOAD
Company
ALUMIS INC.

Letter

February 19, 2025 Martin Babler Chief Executive Officer Alumis Inc. 280 East Grand Avenue South San Francisco, CA 94080 Re:Alumis Inc. Draft Registration Statement on Form S-4 Submitted February 14, 2025 CIK No. 0001847367 Dear Martin Babler: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Dave Peinsipp

Show Raw Text
February 19, 2025
Martin Babler
Chief Executive Officer
Alumis Inc.
280 East Grand Avenue
South San Francisco, CA 94080
Re:Alumis Inc.
Draft Registration Statement on Form S-4
Submitted February 14, 2025
CIK No. 0001847367
Dear Martin Babler:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours
prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding
requests for acceleration. We remind you that the company and its management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Dave Peinsipp